News briefs from Genmab/Kyowa Hakko; Alimera/Quintiles; Novo Nordisk; Astellas; Sandoz

5 December 2012

Denmark-based Genmab (GEN: CO) and Japan’s Kyowa Hakko (TYO: 4151) K have entered into a license agreement to develop bispecific antibodies using Genmab’s DuoBody technology. Specific financial details were not disclosed. Genmab confirmed that the deal will not have a material impact on its 2012 financial outlook.

Marketing deal for Iluvien

USA-based Alimera Sciences (Nasdaq: ALIM) and Quintiles have signed a services agreement for the commercial launch of Iluvien (fluocinolone acetonide intravitreal insert) in certain European countries for chronic diabetic macular edema. Under the deal, Services provided by Quintiles may include marketing, brand management, sales promotion and detailing, market access, regulatory, medical science liaison and communications and advisory.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK